| Title: | L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis |
| Authors: | Ohara, Masatsugu Browse this author |
| Ogawa, Koji Browse this author |
| Suda, Goki Browse this author →KAKEN DB |
| Kimura, Megumi Browse this author |
| Maehara, Osamu Browse this author |
| Shimazaki, Tomoe Browse this author |
| Suzuki, Kazuharu Browse this author |
| Nakamura, Akihisa Browse this author |
| Umemura, Machiko Browse this author |
| Izumi, Takaaki Browse this author |
| Kawagishi, Naoki Browse this author |
| Nakai, Masato Browse this author |
| Sho, Takuya Browse this author |
| Natsuizaka, Mitsuteru Browse this author |
| Morikawa, Kenichi Browse this author |
| Ohnishi, Shunsuke Browse this author →KAKEN DB |
| Sakamoto, Naoya Browse this author →KAKEN DB |
| Issue Date: | Aug-2018 |
| Publisher: | John Wiley & Sons |
| Journal Title: | Hepatology communications |
| Volume: | 2 |
| Issue: | 8 |
| Start Page: | 910 |
| End Page: | 922 |
| Publisher DOI: | 10.1002/hep4.1207 |
| Abstract: | Liver cirrhosis (LC) is a major cause of secondary sarcopenia. Sarcopenia makes the prognosis worse; thus, novel therapeutic options for sarcopenia in patients with LC are urgently required as they are currently limited. In this retrospective study, 158 patients with LC were screened, and 35 of those patients who were treated with L-carnitine for more than 6 months and for whom skeletal muscle mass changes could he evaluated by computer tomography were enrolled. Of the 158 patients, 79 patients who did not receive L-carnitine supplementation served as controls. Cases and controls were propensity score matched for age, sex, presence of hepatocellular carcinoma, and branched chain amino acid administration, and changes in skeletal muscle mass and clinical data were compared. The 35 patients who received L-carnitine supplementation and 35 propensity score-matched patients who did not receive carnitine supplementation comprised the final enrollment. Compared with control patients, patients who received L-carnitine had significantly worse liver function, which is associated with rapid progress of skeletal muscle depletion. However, loss of skeletal muscle mass was significantly suppressed in patients receiving L-carnitine, and a significant effect was observed in patient subgroups stratified by age, sex, presence of hepatocellular carcinoma, and branched chain amino acid administration. The change ratios of most laboratory data, including vitamin D and insulin-like growth factor 1 levels, were similar in the two groups, but ammonia levels were significantly less in those receiving L-carnitine. However, even in patients receiving L-carnitine but not showing an ammonia decrease, loss of skeletal muscle was significantly suppressed. Conclusion: L-carnitine suppresses loss of skeletal muscle mass and may therefore be a novel therapeutic option for sarcopenia in patients with LC. |
| Rights: | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| Type: | article |
| URI: | http://hdl.handle.net/2115/72965 |
| Appears in Collections: | 北海道大学病院 (Hokkaido University Hospital) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
